213 related articles for article (PubMed ID: 36839259)
1. Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson's Disease: A Meta-Analysis.
Kim JH; Jin S; Eo H; Oh MS; Lim Y
Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839259
[TBL] [Abstract][Full Text] [Related]
2. Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
Anamnart C; Kitjarak R
J Clin Neurosci; 2021 Jun; 88():226-231. PubMed ID: 33992189
[TBL] [Abstract][Full Text] [Related]
3. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis.
Hu XW; Qin SM; Li D; Hu LF; Liu CF
Acta Neurol Scand; 2013 Aug; 128(2):73-82. PubMed ID: 23432663
[TBL] [Abstract][Full Text] [Related]
4. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
[TBL] [Abstract][Full Text] [Related]
5. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
[TBL] [Abstract][Full Text] [Related]
6. Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson's disease: clinical and therapeutic considerations.
Phokaewvarangkul O; Bhidayasiri R; Garcia-Ruiz P; Odin P; Riederer P; Müller T
J Neural Transm (Vienna); 2023 Nov; 130(11):1451-1462. PubMed ID: 37603058
[TBL] [Abstract][Full Text] [Related]
7. Features of Plasma Homocysteine, Vitamin B12, and Folate in Parkinson's Disease: An Updated Meta-Analysis.
Liu Y; Gou M; Guo X
J Integr Neurosci; 2023 Aug; 22(5):115. PubMed ID: 37735121
[TBL] [Abstract][Full Text] [Related]
8. Plasma homocysteine, folate and vitamin B12 levels in Parkinson's disease in China: A meta-analysis.
Dong B; Wu R
Clin Neurol Neurosurg; 2020 Jan; 188():105587. PubMed ID: 31733593
[TBL] [Abstract][Full Text] [Related]
9. The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.
Triantafyllou NI; Kararizou E; Angelopoulos E; Tsounis S; Boufidou F; Evangelopoulos ME; Nikolaou C; Vassilopoulos D
Eur Neurol; 2007; 58(2):96-9. PubMed ID: 17565222
[TBL] [Abstract][Full Text] [Related]
10. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
[TBL] [Abstract][Full Text] [Related]
11. Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review.
Zoccolella S; Iliceto G; deMari M; Livrea P; Lamberti P
Clin Chem Lab Med; 2007; 45(12):1607-13. PubMed ID: 17963454
[TBL] [Abstract][Full Text] [Related]
12. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration.
Lamberti P; Zoccolella S; Armenise E; Lamberti SV; Fraddosio A; de Mari M; Iliceto G; Livrea P
Eur J Neurol; 2005 May; 12(5):365-8. PubMed ID: 15804266
[TBL] [Abstract][Full Text] [Related]
13. Association between the risk and severity of Parkinson's disease and plasma homocysteine, vitamin B12 and folate levels: a systematic review and meta-analysis.
Quan Y; Xu J; Xu Q; Guo Z; Ou R; Shang H; Wei Q
Front Aging Neurosci; 2023; 15():1254824. PubMed ID: 37941998
[TBL] [Abstract][Full Text] [Related]
14. Correlations Between Methionine Cycle Metabolism, COMT Genotype, and Polyneuropathy in L-Dopa Treated Parkinson's Disease: A Preliminary Cross-Sectional Study.
Andréasson M; Brodin L; Laffita-Mesa JM; Svenningsson P
J Parkinsons Dis; 2017; 7(4):619-628. PubMed ID: 28759974
[TBL] [Abstract][Full Text] [Related]
15. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions.
Zoccolella S; Lamberti P; Iliceto G; Diroma C; Armenise E; Defazio G; Lamberti SV; Fraddosio A; de Mari M; Livrea P
Clin Chem Lab Med; 2005; 43(10):1107-10. PubMed ID: 16197306
[TBL] [Abstract][Full Text] [Related]
16. Is the deficiency of vitamin B12 related to oxidative stress and neurotoxicity in Parkinson's patients?
Qureshi GA; Qureshi AA; Devrajani BR; Chippa MA; Syed SA
CNS Neurol Disord Drug Targets; 2008 Feb; 7(1):20-7. PubMed ID: 18289028
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of Homocysteine, Vitamin B12 and Folate in Patients with Multiple Sclerosis: an Updated Meta-Analysis.
Li X; Yuan J; Han J; Hu W
Int J Med Sci; 2020; 17(6):751-761. PubMed ID: 32218697
[No Abstract] [Full Text] [Related]
18. Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Müller T; Woitalla D; Muhlack S
Naunyn Schmiedebergs Arch Pharmacol; 2011 Jun; 383(6):627-33. PubMed ID: 21533995
[TBL] [Abstract][Full Text] [Related]
19. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
[TBL] [Abstract][Full Text] [Related]
20. Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson's disease: A meta-analysis.
Xie Y; Feng H; Peng S; Xiao J; Zhang J
Neurosci Lett; 2017 Jan; 636():190-195. PubMed ID: 27840145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
